Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2004 Oct;59(10):904–909. doi: 10.1136/thx.2003.006551

α1-Antitrypsin deficiency · 6: New and emerging treatments for α1-antitrypsin deficiency

R Sandhaus
PMCID: PMC1746849  PMID: 15454659

Abstract

Alpha-1-antitrypsin (AAT) deficiency is a genetic condition that increases the risk of developing lung and liver disease, as well as other associated conditions. Most treatment of affected individuals is not specifically directed at AAT deficiency but focuses on the resultant disease state. The only currently available specific therapeutic agent—namely, intravenous augmentation with plasma derived AAT protein—is marketed in a limited number of countries. Treatments aimed at correcting the underlying genetic abnormality, supplementing or modifying the gene product, and halting or reversing organ injury are now beginning to emerge. These innovative approaches may prove effective at modifying or eliminating diseases association with AAT deficiency.

Full Text

The Full Text of this article is available as a PDF (89.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agarwal Sheba, Gamper Howard B., Kmiec Eric B. Nucleotide replacement at two sites can be directed by modified single-stranded oligonucleotides in vitro and in vivo. Biomol Eng. 2003 Jan;20(1):7–20. doi: 10.1016/s1389-0344(02)00088-6. [DOI] [PubMed] [Google Scholar]
  2. Barnes P. J. Genetics and pulmonary medicine. 9. Molecular genetics of chronic obstructive pulmonary disease. Thorax. 1999 Mar;54(3):245–252. doi: 10.1136/thx.54.3.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baslund B., Szpirt W., Eriksson S., Elzouki A. N., Wiik A., Wieslander J., Petersen J. Complexes between proteinase 3, alpha 1-antitrypsin and proteinase 3 anti-neutrophil cytoplasm autoantibodies: a comparison between alpha 1-antitrypsin PiZ allele carriers and non-carriers with Wegener's granulomatosis. Eur J Clin Invest. 1996 Sep;26(9):786–792. doi: 10.1046/j.1365-2362.1996.2070553.x. [DOI] [PubMed] [Google Scholar]
  4. Beckman G., Stjernberg N. L., Eklund A. Is the PiF allele of alpha 1-antitrypsin associated with pulmonary disease? Clin Genet. 1984 Jun;25(6):491–495. [PubMed] [Google Scholar]
  5. Billingsley G. D., Walter M. A., Hammond G. L., Cox D. W. Physical mapping of four serpin genes: alpha 1-antitrypsin, alpha 1-antichymotrypsin, corticosteroid-binding globulin, and protein C inhibitor, within a 280-kb region on chromosome I4q32.1. Am J Hum Genet. 1993 Feb;52(2):343–353. [PMC free article] [PubMed] [Google Scholar]
  6. Brantly M., Nukiwa T., Crystal R. G. Molecular basis of alpha-1-antitrypsin deficiency. Am J Med. 1988 Jun 24;84(6A):13–31. doi: 10.1016/0002-9343(88)90154-4. [DOI] [PubMed] [Google Scholar]
  7. Burrows J. A., Willis L. K., Perlmutter D. H. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1796–1801. doi: 10.1073/pnas.97.4.1796. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cadène M., Duranton J., North A., Si-Tahar M., Chignard M., Bieth J. G. Inhibition of neutrophil serine proteinases by suramin. J Biol Chem. 1997 Apr 11;272(15):9950–9955. doi: 10.1074/jbc.272.15.9950. [DOI] [PubMed] [Google Scholar]
  9. Campbell E. J., Senior R. M., McDonald J. A., Cox D. L. Proteolysis by neutrophils. Relative importance of cell-substrate contact and oxidative inactivation of proteinase inhibitors in vitro. J Clin Invest. 1982 Oct;70(4):845–852. doi: 10.1172/JCI110681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cantor J. O., Cerreta J. M., Armand G., Turino G. M. Aerosolized hyaluronic acid decreases alveolar injury induced by human neutrophil elastase. Proc Soc Exp Biol Med. 1998 Apr;217(4):471–475. doi: 10.3181/00379727-217-44260. [DOI] [PubMed] [Google Scholar]
  11. Cantor J. O., Cerreta J. M., Keller S., Turino G. M. Modulation of airspace enlargement in elastase-induced emphysema by intratracheal instillment of hyaluronidase and hyaluronic acid. Exp Lung Res. 1995 May-Jun;21(3):423–436. doi: 10.3109/01902149509023717. [DOI] [PubMed] [Google Scholar]
  12. Carlson J. A., Rogers B. B., Sifers R. N., Finegold M. J., Clift S. M., DeMayo F. J., Bullock D. W., Woo S. L. Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice. J Clin Invest. 1989 Apr;83(4):1183–1190. doi: 10.1172/JCI113999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Carp H., Janoff A. Possible mechanisms of emphysema in smokers. In vitro suppression of serum elastase-inhibitory capacity by fresh cigarette smoke and its prevention by antioxidants. Am Rev Respir Dis. 1978 Sep;118(3):617–621. doi: 10.1164/arrd.1978.118.3.617. [DOI] [PubMed] [Google Scholar]
  14. Carrell Robin W., Lomas David A. Alpha1-antitrypsin deficiency--a model for conformational diseases. N Engl J Med. 2002 Jan 3;346(1):45–53. doi: 10.1056/NEJMra010772. [DOI] [PubMed] [Google Scholar]
  15. Casolaro M. A., Fells G., Wewers M., Pierce J. E., Ogushi F., Hubbard R., Sellers S., Forstrom J., Lyons D., Kawasaki G. Augmentation of lung antineutrophil elastase capacity with recombinant human alpha-1-antitrypsin. J Appl Physiol (1985) 1987 Nov;63(5):2015–2023. doi: 10.1152/jappl.1987.63.5.2015. [DOI] [PubMed] [Google Scholar]
  16. Cole-Strauss A., Gamper H., Holloman W. K., Muñoz M., Cheng N., Kmiec E. B. Targeted gene repair directed by the chimeric RNA/DNA oligonucleotide in a mammalian cell-free extract. Nucleic Acids Res. 1999 Mar 1;27(5):1323–1330. doi: 10.1093/nar/27.5.1323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Dirksen A., Dijkman J. H., Madsen F., Stoel B., Hutchison D. C., Ulrik C. S., Skovgaard L. T., Kok-Jensen A., Rudolphus A., Seersholm N. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1468–1472. doi: 10.1164/ajrccm.160.5.9901055. [DOI] [PubMed] [Google Scholar]
  18. Domínguez-Bendala Juan, Ricordi Camillo. Stem cell therapies in reparative medicine. Cell Transplant. 2003;12(4):329–334. doi: 10.3727/000000003108746849. [DOI] [PubMed] [Google Scholar]
  19. Edwards P. D., Bernstein P. R. Synthetic inhibitors of elastase. Med Res Rev. 1994 Mar;14(2):127–194. doi: 10.1002/med.2610140202. [DOI] [PubMed] [Google Scholar]
  20. Elliott P. R., Bilton D., Lomas D. A. Lung polymers in Z alpha1-antitrypsin deficiency-related emphysema. Am J Respir Cell Mol Biol. 1998 May;18(5):670–674. doi: 10.1165/ajrcmb.18.5.3065. [DOI] [PubMed] [Google Scholar]
  21. Eriksson S. Alpha 1-antitrypsin deficiency and liver cirrhosis in adults. An analysis of 35 Swedish autopsied cases. Acta Med Scand. 1987;221(5):461–467. [PubMed] [Google Scholar]
  22. Eriksson S., Carlson J., Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med. 1986 Mar 20;314(12):736–739. doi: 10.1056/NEJM198603203141202. [DOI] [PubMed] [Google Scholar]
  23. Fagerhol M. K., Laurell C. B. The Pi system-inherited variants of serum alpha 1-antitrypsin. Prog Med Genet. 1970;7:96–111. [PubMed] [Google Scholar]
  24. Flotte Terence R. Recombinant adeno-associated virus gene therapy for cystic fibrosis and alpha(1)-antitrypsin deficiency. Chest. 2002 Mar;121(3 Suppl):98S–102S. doi: 10.1378/chest.121.3_suppl.98s. [DOI] [PubMed] [Google Scholar]
  25. Gadek J. E., Fells G. A., Crystal R. G. Cigarette smoking induces functional antiprotease deficiency in the lower respiratory tract of humans. Science. 1979 Dec 14;206(4424):1315–1316. doi: 10.1126/science.316188. [DOI] [PubMed] [Google Scholar]
  26. Gadek J. E., Fells G. A., Zimmerman R. L., Rennard S. I., Crystal R. G. Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema. J Clin Invest. 1981 Oct;68(4):889–898. doi: 10.1172/JCI110344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Ganrot P. O., Laurell C. B., Eriksson S. Obstructive lung disease and trypsin inhibitors in alpha-1-antitrypsin deficiency. Scand J Clin Lab Invest. 1967;19(3):205–208. doi: 10.3109/00365516709090627. [DOI] [PubMed] [Google Scholar]
  28. Hautamaki R. D., Kobayashi D. K., Senior R. M., Shapiro S. D. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science. 1997 Sep 26;277(5334):2002–2004. doi: 10.1126/science.277.5334.2002. [DOI] [PubMed] [Google Scholar]
  29. Hu C., Perlmutter D. H. Regulation of alpha1-antitrypsin gene expression in human intestinal epithelial cell line caco-2 by HNF-1alpha and HNF-4. Am J Physiol. 1999 May;276(5 Pt 1):G1181–G1194. doi: 10.1152/ajpgi.1999.276.5.G1181. [DOI] [PubMed] [Google Scholar]
  30. Hubbard R. C., Brantly M. L., Sellers S. E., Mitchell M. E., Crystal R. G. Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin. Ann Intern Med. 1989 Aug 1;111(3):206–212. doi: 10.7326/0003-4819-111-3-206. [DOI] [PubMed] [Google Scholar]
  31. Hubbard R. C., Crystal R. G. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Lung. 1990;168 (Suppl):565–578. doi: 10.1007/BF02718179. [DOI] [PubMed] [Google Scholar]
  32. Hubbard R. C., Ogushi F., Fells G. A., Cantin A. M., Jallat S., Courtney M., Crystal R. G. Oxidants spontaneously released by alveolar macrophages of cigarette smokers can inactivate the active site of alpha 1-antitrypsin, rendering it ineffective as an inhibitor of neutrophil elastase. J Clin Invest. 1987 Nov;80(5):1289–1295. doi: 10.1172/JCI113204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Janoff A., Carp H., Laurent P., Raju L. The role of oxidative processes in emphysema. Am Rev Respir Dis. 1983 Feb;127(2):S31–S38. doi: 10.1164/arrd.1983.127.2P2.S31. [DOI] [PubMed] [Google Scholar]
  34. Janoff A., Carp H., Lee D. K., Drew R. T. Cigarette smoke inhalation decreases alpha 1-antitrypsin activity in rat lung. Science. 1979 Dec 14;206(4424):1313–1314. doi: 10.1126/science.316187. [DOI] [PubMed] [Google Scholar]
  35. Janoff A. Inhibition of human granulocyte elastase by serum alpha-1-antitrypsin. Am Rev Respir Dis. 1972 Jan;105(1):121–122. doi: 10.1164/arrd.1972.105.1.121. [DOI] [PubMed] [Google Scholar]
  36. Janoff A., Sandhaus R. A., Hospelhorn V. D., Rosenberg R. Digestion of lung proteins by human leukocyte granules in vitro. Proc Soc Exp Biol Med. 1972 Jun;140(2):516–519. doi: 10.3181/00379727-140-36493. [DOI] [PubMed] [Google Scholar]
  37. Kasahara Y., Tuder R. M., Taraseviciene-Stewart L., Le Cras T. D., Abman S., Hirth P. K., Waltenberger J., Voelkel N. F. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000 Dec;106(11):1311–1319. doi: 10.1172/JCI10259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Kawabata K., Suzuki M., Sugitani M., Imaki K., Toda M., Miyamoto T. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun. 1991 Jun 14;177(2):814–820. doi: 10.1016/0006-291x(91)91862-7. [DOI] [PubMed] [Google Scholar]
  39. Kay M. A., Graham F., Leland F., Woo S. L. Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes. Hepatology. 1995 Mar;21(3):815–819. [PubMed] [Google Scholar]
  40. Kinnula Vuokko L., Crapo James D. Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med. 2003 Jun 15;167(12):1600–1619. doi: 10.1164/rccm.200212-1479SO. [DOI] [PubMed] [Google Scholar]
  41. Konno K., Arai H., Motomiya M., Nagai H., Ito M., Sato H., Satoh K. A biochemical study on glycosaminoglycans (mucopolysaccharides) in emphysematous and in aged lungs. Am Rev Respir Dis. 1982 Nov;126(5):797–801. doi: 10.1164/arrd.1982.126.5.797. [DOI] [PubMed] [Google Scholar]
  42. Kurachi K., Chandra T., Degen S. J., White T. T., Marchioro T. L., Woo S. L., Davie E. W. Cloning and sequence of cDNA coding for alpha 1-antitrypsin. Proc Natl Acad Sci U S A. 1981 Nov;78(11):6826–6830. doi: 10.1073/pnas.78.11.6826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Laurell C. B. Is emphysema in alpha 1 -antitrypsin deficiency a result of autodigestion? Scand J Clin Lab Invest. 1971 Sep;28(1):1–3. doi: 10.3109/00365517109090655. [DOI] [PubMed] [Google Scholar]
  44. Lee J. H., Brantly M. Molecular mechanisms of alpha1-antitrypsin null alleles. Respir Med. 2000 Aug;94 (Suppl 100):S7–11. doi: 10.1053/rmed.2000.0851. [DOI] [PubMed] [Google Scholar]
  45. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest. 2000 Nov;118(5):1480–1485. doi: 10.1378/chest.118.5.1480. [DOI] [PubMed] [Google Scholar]
  46. Lieberman J. Heterozygous and homozygous alpha-antitrypsin deficiency in patients with pulmonary emphysema. N Engl J Med. 1969 Aug 7;281(6):279–284. doi: 10.1056/NEJM196908072810601. [DOI] [PubMed] [Google Scholar]
  47. Lieberman J., Winter B., Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest. 1986 Mar;89(3):370–373. doi: 10.1378/chest.89.3.370. [DOI] [PubMed] [Google Scholar]
  48. Lomas D. A., Evans D. L., Finch J. T., Carrell R. W. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992 Jun 18;357(6379):605–607. doi: 10.1038/357605a0. [DOI] [PubMed] [Google Scholar]
  49. Longstreth G. F., Weitzman S. A., Browning R. J., Lieberman J. Bronchiectasis and homozygous alpha1-antitrypsin deficiency. Chest. 1975 Feb;67(2):233–235. doi: 10.1378/chest.67.2.233. [DOI] [PubMed] [Google Scholar]
  50. Luisetti M., Sturani C., Sella D., Madonini E., Galavotti V., Bruno G., Peona V., Kucich U., Dagnino G., Rosenbloom J. MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur Respir J. 1996 Jul;9(7):1482–1486. doi: 10.1183/09031936.96.09071482. [DOI] [PubMed] [Google Scholar]
  51. Mahadeva R., Lomas D. A. Genetics and respiratory disease. 2. Alpha 1-antitrypsin deficiency, cirrhosis and emphysema. Thorax. 1998 Jun;53(6):501–505. doi: 10.1136/thx.53.6.501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Mahadeva Ravi, Dafforn Timothy R., Carrell Robin W., Lomas David A. 6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z alpha(1)-antitrypsin-related cirrhosis. J Biol Chem. 2001 Dec 28;277(9):6771–6774. doi: 10.1074/jbc.C100722200. [DOI] [PubMed] [Google Scholar]
  53. Mao Jenny T., Goldin Jonathan G., Dermand John, Ibrahim Grace, Brown Mathew S., Emerick Aletha, McNitt-Gray Michael F., Gjertson David W., Estrada Francine, Tashkin Donald P. A pilot study of all-trans-retinoic acid for the treatment of human emphysema. Am J Respir Crit Care Med. 2002 Mar 1;165(5):718–723. doi: 10.1164/ajrccm.165.5.2106123. [DOI] [PubMed] [Google Scholar]
  54. Massaro G. D., Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med. 1997 Jun;3(6):675–677. doi: 10.1038/nm0697-675. [DOI] [PubMed] [Google Scholar]
  55. Mayer A. S., Stoller J. K., Bucher Bartelson B., James Ruttenber A., Sandhaus R. A., Newman L. S. Occupational exposure risks in individuals with PI*Z alpha(1)-antitrypsin deficiency. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):553–558. doi: 10.1164/ajrccm.162.2.9907117. [DOI] [PubMed] [Google Scholar]
  56. Novoradovskaya N., Lee J., Yu Z. X., Ferrans V. J., Brantly M. Inhibition of intracellular degradation increases secretion of a mutant form of alpha1-antitrypsin associated with profound deficiency. J Clin Invest. 1998 Jun 15;101(12):2693–2701. doi: 10.1172/JCI549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. O'Riordan K., Blei A., Rao M. S., Abecassis M. alpha 1-antitrypsin deficiency-associated panniculitis: resolution with intravenous alpha 1-antitrypsin administration and liver transplantation. Transplantation. 1997 Feb 15;63(3):480–482. doi: 10.1097/00007890-199702150-00028. [DOI] [PubMed] [Google Scholar]
  58. Ostroukhova Marina, Seguin-Devaux Carole, Oriss Timothy B., Dixon-McCarthy Barbara, Yang Liyan, Ameredes Bill T., Corcoran Timothy E., Ray Anuradha. Tolerance induced by inhaled antigen involves CD4(+) T cells expressing membrane-bound TGF-beta and FOXP3. J Clin Invest. 2004 Jul;114(1):28–38. doi: 10.1172/JCI20509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Ozaki I., Zern M. A., Liu S., Wei D. L., Pomerantz R. J., Duan L. Ribozyme-mediated specific gene replacement of the alpha1-antitrypsin gene in human hepatoma cells. J Hepatol. 1999 Jul;31(1):53–60. doi: 10.1016/s0168-8278(99)80163-9. [DOI] [PubMed] [Google Scholar]
  60. Panyutich A. V., Hiemstra P. S., van Wetering S., Ganz T. Human neutrophil defensin and serpins form complexes and inactivate each other. Am J Respir Cell Mol Biol. 1995 Mar;12(3):351–357. doi: 10.1165/ajrcmb.12.3.7873202. [DOI] [PubMed] [Google Scholar]
  61. Parfrey Helen, Mahadeva Ravi, Lomas David A. Alpha(1)-antitrypsin deficiency, liver disease and emphysema. Int J Biochem Cell Biol. 2003 Jul;35(7):1009–1014. doi: 10.1016/s1357-2725(02)00250-9. [DOI] [PubMed] [Google Scholar]
  62. Parfrey Helen, Mahadeva Ravi, Ravenhill Neil A., Zhou Aiwu, Dafforn Timothy R., Foreman Richard C., Lomas David A. Targeting a surface cavity of alpha 1-antitrypsin to prevent conformational disease. J Biol Chem. 2003 Jun 13;278(35):33060–33066. doi: 10.1074/jbc.M302646200. [DOI] [PubMed] [Google Scholar]
  63. Parmar Jasvir S., Mahadeva Ravi, Reed Benjamin J., Farahi Neda, Cadwallader Karen A., Keogan Mary T., Bilton Diana, Chilvers Edwin R., Lomas David A. Polymers of alpha(1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am J Respir Cell Mol Biol. 2002 Jun;26(6):723–730. doi: 10.1165/ajrcmb.26.6.4739. [DOI] [PubMed] [Google Scholar]
  64. Repine J. E., Bast A., Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):341–357. doi: 10.1164/ajrccm.156.2.9611013. [DOI] [PubMed] [Google Scholar]
  65. Rouhani F, Paone G, Smith NK, Krein P, Barnes P, Brantly ML. Lung neutrophil burden correlates with increased pro-inflammatory cytokines and decreased lung function in individuals with alpha(1)-antitrypsin deficiency. Chest. 2000 May;117(5 Suppl 1):250S–251S. doi: 10.1378/chest.117.5_suppl_1.250s. [DOI] [PubMed] [Google Scholar]
  66. Rubinstein H. M., Jaffer A. M., Kudrna J. C., Lertratanakul Y., Chandrasekhar A. J., Slater D., Schmid F. R. Alpha1-antitrypsin deficiency with severe panniculitis. Report of two cases. Ann Intern Med. 1977 Jun;86(6):742–744. doi: 10.7326/0003-4819-86-6-742. [DOI] [PubMed] [Google Scholar]
  67. Sandford A. J., Weir T. D., Paré P. D. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J. 1997 Jun;10(6):1380–1391. doi: 10.1183/09031936.97.10061380. [DOI] [PubMed] [Google Scholar]
  68. Sandhaus R. A. Alpha 1-antitrypsin augmentation therapy. Agents Actions Suppl. 1993;42:97–102. [PubMed] [Google Scholar]
  69. Scobie G., Jasani B., Kalsheker N. Non-specific effects of anti-sense oligonucleotides on alpha-1-antitrypsin expression in Cos cells transfected with alpha-1-antitrypsin cDNA constructs. Biochem Soc Trans. 1992 Nov;20(4):319S–319S. doi: 10.1042/bst020319s. [DOI] [PubMed] [Google Scholar]
  70. Seersholm N., Wencker M., Banik N., Viskum K., Dirksen A., Kok-Jensen A., Konietzko N. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J. 1997 Oct;10(10):2260–2263. doi: 10.1183/09031936.97.10102260. [DOI] [PubMed] [Google Scholar]
  71. Segelmark M., Elzouki A. N., Wieslander J., Eriksson S. The PiZ gene of alpha 1-antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis. Kidney Int. 1995 Sep;48(3):844–850. doi: 10.1038/ki.1995.360. [DOI] [PubMed] [Google Scholar]
  72. Shapiro S. D. Elastolytic metalloproteinases produced by human mononuclear phagocytes. Potential roles in destructive lung disease. Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 2):S160–S164. doi: 10.1164/ajrccm/150.6_Pt_2.S160. [DOI] [PubMed] [Google Scholar]
  73. Sharp H. L., Bridges R. A., Krivit W., Freier E. F. Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder. J Lab Clin Med. 1969 Jun;73(6):934–939. [PubMed] [Google Scholar]
  74. Silverman E. K., Chapman H. A., Drazen J. M., Weiss S. T., Rosner B., Campbell E. J., O'DONNELL W. J., Reilly J. J., Ginns L., Mentzer S. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1770–1778. doi: 10.1164/ajrccm.157.6.9706014. [DOI] [PubMed] [Google Scholar]
  75. Silverman E. K., Miletich J. P., Pierce J. A., Sherman L. A., Endicott S. K., Broze G. J., Jr, Campbell E. J. Alpha-1-antitrypsin deficiency. High prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis. 1989 Oct;140(4):961–966. doi: 10.1164/ajrccm/140.4.961. [DOI] [PubMed] [Google Scholar]
  76. Silverman G. A., Bird P. I., Carrell R. W., Church F. C., Coughlin P. B., Gettins P. G., Irving J. A., Lomas D. A., Luke C. J., Moyer R. W. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem. 2001 Jul 2;276(36):33293–33296. doi: 10.1074/jbc.R100016200. [DOI] [PubMed] [Google Scholar]
  77. Smith K. C., Pittelkow M. R., Su W. P. Panniculitis associated with severe alpha 1-antitrypsin deficiency. Treatment and review of the literature. Arch Dermatol. 1987 Dec;123(12):1655–1661. [PubMed] [Google Scholar]
  78. Smith Kevin R., Uyeminami Dale L., Kodavanti Urmila P., Crapo James D., Chang Ling-Ying, Pinkerton Kent E. Inhibition of tobacco smoke-induced lung inflammation by a catalytic antioxidant. Free Radic Biol Med. 2002 Oct 15;33(8):1106–1114. doi: 10.1016/s0891-5849(02)01003-1. [DOI] [PubMed] [Google Scholar]
  79. Song S., Embury J., Laipis P. J., Berns K. I., Crawford J. M., Flotte T. R. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 2001 Sep;8(17):1299–1306. doi: 10.1038/sj.gt.3301422. [DOI] [PubMed] [Google Scholar]
  80. Song S., Morgan M., Ellis T., Poirier A., Chesnut K., Wang J., Brantly M., Muzyczka N., Byrne B. J., Atkinson M. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14384–14388. doi: 10.1073/pnas.95.24.14384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Song Sihong, Scott-Jorgensen Marda, Wang Jianming, Poirier Amy, Crawford James, Campbell-Thompson Martha, Flotte Terence R. Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects. Mol Ther. 2002 Sep;6(3):329–335. doi: 10.1006/mthe.2002.0673. [DOI] [PubMed] [Google Scholar]
  82. Stockley R. A. The role of proteinases in the pathogenesis of chronic bronchitis. Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 2):S109–S113. doi: 10.1164/ajrccm/150.6_Pt_2.S109. [DOI] [PubMed] [Google Scholar]
  83. Stockley Robert A., Bayley Darren L., Unsal Ipek, Dowson Lee J. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2002 Jun 1;165(11):1494–1498. doi: 10.1164/rccm.2109013. [DOI] [PubMed] [Google Scholar]
  84. Stoller James K., Rouhani Farshid, Brantly Mark, Shahin Seta, Dweik Raed A., Stocks James M., Clausen Jack, Campbell Edward, Norton Frank. Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin. Chest. 2002 Jul;122(1):66–74. doi: 10.1378/chest.122.1.66. [DOI] [PubMed] [Google Scholar]
  85. Sveger T. The natural history of liver disease in alpha 1-antitrypsin deficient children. Acta Paediatr Scand. 1988 Nov;77(6):847–851. doi: 10.1111/j.1651-2227.1988.tb10767.x. [DOI] [PubMed] [Google Scholar]
  86. Thomas C. E., Ohlweiler D. F., Carr A. A., Nieduzak T. R., Hay D. A., Adams G., Vaz R., Bernotas R. C. Characterization of the radical trapping activity of a novel series of cyclic nitrone spin traps. J Biol Chem. 1996 Feb 9;271(6):3097–3104. doi: 10.1074/jbc.271.6.3097. [DOI] [PubMed] [Google Scholar]
  87. Warter J., Storck D., Grosshans E., Metais P., Kuntz J. L., Klumpp T. Syndrome de Weber-Christian associé à un déficit en alpha-I-antitrypsine. Enquéte familiale. Ann Med Interne (Paris) 1972 Oct;123(10):877–882. [PubMed] [Google Scholar]
  88. Wencker M., Banik N., Buhl R., Seidel R., Konietzko N. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Eur Respir J. 1998 Feb;11(2):428–433. doi: 10.1183/09031936.98.11020428. [DOI] [PubMed] [Google Scholar]
  89. Wencker M., Fuhrmann B., Banik N., Konietzko N., Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest. 2001 Mar;119(3):737–744. doi: 10.1378/chest.119.3.737. [DOI] [PubMed] [Google Scholar]
  90. Wewers M. D., Brantly M. L., Casolaro M. A., Crystal R. G. Evaluation of tamoxifen as a therapy to augment alpha-1-antitrypsin concentrations in Z homozygous alpha-1-antitrypsin-deficient subjects. Am Rev Respir Dis. 1987 Feb;135(2):401–402. doi: 10.1164/arrd.1987.135.2.401. [DOI] [PubMed] [Google Scholar]
  91. Wewers M. D., Casolaro M. A., Sellers S. E., Swayze S. C., McPhaul K. M., Wittes J. T., Crystal R. G. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987 Apr 23;316(17):1055–1062. doi: 10.1056/NEJM198704233161704. [DOI] [PubMed] [Google Scholar]
  92. Wewers M. D., Gadek J. E., Keogh B. A., Fells G. A., Crystal R. G. Evaluation of danazol therapy for patients with PiZZ alpha-1-antitrypsin deficiency. Am Rev Respir Dis. 1986 Sep;134(3):476–480. doi: 10.1164/arrd.1986.134.3.476. [DOI] [PubMed] [Google Scholar]
  93. Williams J. C., Falcone R. C., Knee C., Stein R. L., Strimpler A. M., Reaves B., Giles R. E., Krell R. D. Biologic characterization of ICI 200,880 and ICI 200,355, novel inhibitors of human neutrophil elastase. Am Rev Respir Dis. 1991 Oct;144(4):875–883. doi: 10.1164/ajrccm/144.4.875. [DOI] [PubMed] [Google Scholar]
  94. Wright G., Carver A., Cottom D., Reeves D., Scott A., Simons P., Wilmut I., Garner I., Colman A. High level expression of active human alpha-1-antitrypsin in the milk of transgenic sheep. Biotechnology (N Y) 1991 Sep;9(9):830–834. doi: 10.1038/nbt0991-830. [DOI] [PubMed] [Google Scholar]
  95. Zern M. A., Ozaki I., Duan L., Pomerantz R., Liu S. L., Strayer D. S. A novel SV40-based vector successfully transduces and expresses an alpha 1-antitrypsin ribozyme in a human hepatoma-derived cell line. Gene Ther. 1999 Jan;6(1):114–120. doi: 10.1038/sj.gt.3300793. [DOI] [PubMed] [Google Scholar]
  96. Ziomek C. A. Commercialization of proteins produced in the mammary gland. Theriogenology. 1998 Jan 1;49(1):139–144. doi: 10.1016/s0093-691x(97)00408-1. [DOI] [PubMed] [Google Scholar]
  97. de Heer Hendrik Jan, Hammad Hamida, Soullié Thomas, Hijdra Daniëlle, Vos Nanda, Willart Monique A. M., Hoogsteden Henk C., Lambrecht Bart N. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med. 2004 Jul 5;200(1):89–98. doi: 10.1084/jem.20040035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. de Serres Frederick J. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest. 2002 Nov;122(5):1818–1829. doi: 10.1378/chest.122.5.1818. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES